Robinhood, Applovin jump as S&P 500 reshuffle boosts index entrants
Director Roger Jeffs of Axsome Therapeutics (NASDAQ:AXSM), a $6.05 billion biopharmaceutical company that has seen its stock surge nearly 46% year-to-date, sold 13,464 shares of common stock on September 2, 2025, according to a recent SEC filing. The shares were sold at a weighted average price of $123.68, with prices ranging from $121.30 to $124.60, resulting in a total transaction value of $1.66 million.
Following the transaction, Jeffs directly owns 57,510 shares of Axsome Therapeutics. The sale was executed under a pre-approved 10b5-1 trading plan that has now been completed. The filing indicates that the sale represents underlying shares of previously exercised stock options.
In other recent news, Axsome Therapeutics reported its second-quarter 2025 earnings, surpassing Wall Street expectations. The company posted an earnings per share of -$0.97, outperforming the forecast of -$1.06, and revenues reached $150 million, exceeding the anticipated $139.31 million. Additionally, Axsome has received a Paragraph IV Certification Notice Letter from Apotex Inc., which has submitted an Abbreviated New Drug Application to the FDA seeking approval to manufacture a generic version of Symbravo. In response, Axsome plans to address this notice in due course. Analyst firms H.C. Wainwright and Mizuho have reiterated their positive outlooks on Axsome, maintaining Buy and Outperform ratings, respectively, despite the generic challenge. H.C. Wainwright set a price target of $180.00, while Mizuho set a target of $200.00. RBC Capital also reiterated an Outperform rating, citing confidence in the potential approval of Axsome’s AXS-05 drug for Alzheimer’s agitation, with a price target of $189.00. These developments highlight the company’s ongoing strategic challenges and analyst support.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.